Abstract

Recombinant human follicle-stimulating hormone (rhFSH) is a heterodimeric glycoprotein produced via recombinant DNA technology in Chinese hamster ovary (CHO) cells, comprising a 92-amino-acid alpha chain and a 111-amino-acid beta chain, with a molecular weight of approximately 27 kDa. As a gonadotropin essential for follicular development and ovulation induction, rhFSH serves as a cornerstone therapeutic in assisted reproductive technology (ART), including in vitro fertilization (IVF). According to the Global Recombinant Human Follicle-Stimulating Hormone Market Report 2024–2030, the global market is projected to grow from USD 1,460.9 million in 2024 to USD 1,966.4 million by 2030, registering a compound annual growth rate of 5.1% over the forecast period. The competitive landscape is exceptionally concentrated: the top five manufacturers—Merck KGaA, Organon, Gedeon Richter, Ferring, and Changchun High-Tech—collectively accounted for approximately 97.0% of global revenue in 2023. The 75IU dosage form constitutes the dominant product segment at 44.4% share, while women’s infertility treatment represents 73.2% of demand. This analysis examines the therapeutic architecture, the biosimilar entry dynamics reshaping pricing and access, and the regional demand bifurcation between mature Western markets and China’s evolving ART landscape.

Molecular Architecture and Therapeutic Function

rhFSH’s clinical utility derives from its capacity to stimulate ovarian follicular recruitment and maturation, a prerequisite for oocyte retrieval in IVF and other ART procedures. The recombinant production method—expression in CHO cells transfected with optimized DNA sequences encoding the human FSH mature chain—yields a product with consistent glycosylation profiles and batch-to-batch homogeneity superior to urine-derived FSH preparations. This consistency is clinically consequential: dosing precision and predictable pharmacokinetics support controlled ovarian hyperstimulation protocols that balance efficacy against the risk of ovarian hyperstimulation syndrome.

The product taxonomy reflects clinical dosing requirements. The 75IU dosage form, dominant at 44.4% share, serves as the fundamental unit for individualized dosing adjustment, enabling clinicians to titrate gonadotropin administration according to patient response. Higher-strength formulations (150IU and 300IU) reduce the number of injections required per cycle, improving patient convenience and adherence. The market’s gradual shift toward pre-filled pens and ready-to-use formulations reflects the broader trend in injectable biologics toward patient-centric delivery systems that reduce preparation errors and simplify self-administration.

Market Scale and Near-Oligopolistic Concentration

The global rhFSH market is forecast to reach USD 1,966.4 million by 2030 from a 2024 baseline of USD 1,460.9 million, expanding at a CAGR of 5.1%. QYResearch data for the closely related rhFSH injection category place the 2025 market at approximately USD 1.38 billion, with a 2032 trajectory toward USD 1.971 billion at 5.3% CAGR . An earlier QYResearch forecast estimated the 2024 market at USD 1,154 million, growing to USD 1,680 million by 2031 at 5.6% CAGR . The variations in absolute values reflect scope differences—particularly regarding the inclusion of biosimilars and alternative presentation formats—but the growth-rate consensus clusters in the 5%–5.6% range, confirming stable mid-single-digit expansion.

Competitive concentration is among the highest observed in biopharmaceutical markets. In 2023, the top five players held approximately 97.0% of global revenue. Merck KGaA anchors the competitive field through its Gonal-f franchise, the reference product against which biosimilars are benchmarked. Merck’s Fertility business reported 2025 net sales of EUR 1,457 million, with Gonal-f contributing EUR 833 million, though organic growth was marginally positive at 0.4% for the franchise while Gonal-f itself declined 5.1% organically . Organon, the spin-off from Merck & Co., holds a significant position through its fertility portfolio, though the company’s Women’s Health revenue declined 1% as-reported in 2025, with fertility growth in the U.S. offset by weakness in China . Gedeon Richter and Ferring occupy European and global positions, while Changchun High-Tech represents the Chinese domestic supply base through its Jinsai Pharmaceutical subsidiary.

Product Segmentation: Dosage Form and Delivery Innovation

The 75IU dosage form’s 44.4% share reflects its role as the adjustable dosing unit in controlled ovarian stimulation. Clinicians typically initiate treatment at 75–150IU daily and titrate upward based on ultrasound monitoring and estradiol response, making the 75IU presentation essential for individualized protocols. Higher-strength formulations serve patients requiring elevated doses—those with diminished ovarian reserve, polycystic ovary syndrome, or prior poor response—where reducing injection volume and frequency improves the treatment experience.

Delivery innovation constitutes a differentiating competitive dimension. Pre-filled pens with dose-setting dials, thin-wall needles, and integrated dose-history features reduce preparation errors and improve adherence, particularly among patients self-administering at home. The competitive significance of delivery systems is heightened in the biosimilar era: when the active molecule is deemed equivalent, the device becomes a primary locus of brand differentiation.

Application Segmentation: Women’s Infertility Treatment

Women’s infertility treatment represents 73.2% of demand, encompassing ovulation induction in anovulatory women (including those with polycystic ovary syndrome unresponsive to clomiphene citrate), controlled ovarian hyperstimulation for ART procedures (IVF, GIFT, ZIFT), and stimulation in women with severe LH and FSH deficiency. The segment’s dominance reflects the epidemiology of infertility treatment: the vast majority of rhFSH consumption occurs in female patients undergoing fertility intervention.

Male applications—hypogonadotropic hypogonadism, where FSH combined with hCG stimulates spermatogenesis—constitute a smaller but clinically distinct segment. The male segment is less commercially significant in absolute terms but serves a patient population with limited alternative therapeutic options, supporting pricing stability.

Regional Dynamics: Mature Markets and China’s Biosimilar Inflection

North America and Europe constitute the dominant markets for rhFSH, anchored in high ART utilization rates, favorable reimbursement frameworks, and the concentration of leading fertility clinics. The United States, in particular, represents a high-value market where per-cycle gonadotropin costs are substantial and where Organon reported fertility growth in 2025 before anticipated competitive pressure from a competitor’s agreement with the administration’s Direct Access Program .

China represents the most consequential regional inflection point. The Chinese ART market has expanded rapidly, driven by delayed childbearing, changing social policies, and increasing awareness of fertility solutions. However, the entry of domestic biosimilars is reshaping the competitive landscape. In May 2025, Chengdu Jingze Biopharma received NMPA approval for Zepanxi® (recombinant human FSH for injection), a biosimilar developed according to established comparability principles. The Phase III trial enrolled 348 subjects and demonstrated equivalence to the reference product (Gonal-f) across key efficacy endpoints including oocyte retrieval count, MII oocyte count, high-quality embryo rate, and clinical pregnancy rate, with comparable safety profiles; the trial supported the birth of nearly 100 infants . Jingze has indicated plans to launch aqueous and long-acting formulations following Zepanxi® .

The biosimilar entry has implications beyond China. Biosimilar competition in the Chinese market—the world’s most populous ART market—exerts downward pressure on pricing and creates a reference point for biosimilar approvals in other jurisdictions. Organon’s acknowledgment that China represented a headwind in 2025, with socioeconomic trends weighing on the broader fertility market, reflects this evolving dynamic .

Market Drivers and Constraints

The primary demand catalyst is the expansion of ART utilization globally. Delayed childbearing in developed economies, rising infertility prevalence attributable to environmental and lifestyle factors, and increasing public awareness and acceptance of fertility treatment all contribute to growing rhFSH consumption. The segment’s growth is structurally supported by demographic trends that show no sign of reversal.

Biosimilar competition constitutes a second driver—not of volume growth, but of access expansion. Lower-cost biosimilars reduce the financial barrier to ART in price-sensitive markets, potentially expanding the treated population. However, this dynamic also compresses brand revenue, as evidenced by Gonal-f’s organic decline . The net effect on market value depends on the balance between volume expansion and price erosion, which varies by geography.

The principal constraint is the high cost of treatment. A single ART cycle may require thousands of dollars in gonadotropin therapy, and most health insurance systems provide limited or no coverage for fertility treatment. This cost barrier limits the addressable patient population, particularly in markets without public funding or employer-sponsored fertility benefits. Regulatory hurdles—biosimilar approval pathways, clinical trial requirements, and post-marketing surveillance—constitute a secondary constraint on new entrant velocity.

Opportunity Landscape: Long-Acting Formulations and Emerging Markets

Long-acting rhFSH formulations represent the most significant product opportunity. Sustained-release preparations that reduce injection frequency from daily to weekly or per-cycle administration would improve patient convenience and adherence, potentially commanding premium pricing. Several manufacturers, including Chinese entrants, are developing long-acting variants as follow-on products to their biosimilar franchises .

Emerging market expansion constitutes a second opportunity. As ART infrastructure develops in Southeast Asia, Latin America, and the Middle East, demand for affordable gonadotropins grows. Biosimilar suppliers with cost-competitive manufacturing and regulatory pathways for emerging-market approvals are positioned to capture this demand, though pricing pressure will be intense.

Outlook Through 2030

The rhFSH market trajectory through 2030 is characterized by stable but moderating growth anchored in ART utilization and biosimilar-driven access expansion. The 5.1% CAGR reflects a mature therapeutic category in which volume growth is partially offset by price erosion from biosimilar competition. The competitive landscape will be shaped by three forces: the pace of biosimilar adoption in China and other price-sensitive markets; the differentiation potential of delivery systems and long-acting formulations; and the resilience of Merck’s Gonal-f franchise and Organon’s fertility portfolio against biosimilar and generic competition. The therapeutic’s fundamental value proposition—consistent, predictable ovarian stimulation—remains intact. The competitive question is whether incumbent brands can defend premium pricing through device innovation and clinical evidence, or whether the market converges toward biosimilar parity in which cost and access determine market share.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp